stockrow
Friday 6 November 2026
Export TMCI’s income statement to Excel — free account
Treace Medical Concepts, Inc.
TMCI Healthcare Medical Devices
Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024.
- Revenue
- −3.91%
- EPS
- +26.9%
- Free cash flow
- +54.4%
- Total debt
- +5.11%
Quarter to September 2026, against a year earlier
3.95
0.23
−5.50%
Follow TMCI
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.73 | 0.42 | 1.26 | 1.43 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.31) | 11.96 | (55.11) | (89.30) | |
P/B ratio |
1.77 | 1.12 | 3.82 | 4.72 | |
Price to Tangible BV |
2.30 | 1.51 | 5.36 | 6.85 | |
EV/Sales |
0.77 | 0.45 | 1.32 | 1.52 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(10.27) | (7.14) | (18.60) | (35.35) | |
EV/FCF |
(5.56) | (3.56) | (10.82) | (16.63) | |
Quick Ratio |
2.95 | 2.38 | 1.79 | 1.52 | |
Current Ratio |
4.31 | 3.58 | 2.90 | 2.58 | |
Net Debt/EBITDA |
(2.37) | (0.25) | (0.81) | 0.00 | |
Debt/Assets |
29.17% | 30.32% | 30.95% | 31.38% | |
Debt/Equity |
0.64 | 0.72 | 0.83 | 0.91 | |
Asset Turnover |
1.04 | 1.06 | 1.06 | 1.08 | |
Operating CF/Net income |
0.85 | (0.40) | 0.30 | 0.26 | |
Capex/Depreciation |
(0.83) | (2.63) | (1.03) | 0.00 | |
Interest Coverage |
(4.39) | (10.93) | (9.58) | (7.28) | |
Research and Development Expense of Revenue |
7.26% | 9.79% | 9.64% | 9.31% | |
Selling, General and Administrative Expense of Revenue |
82.82% | 105.83% | 101.79% | 94.07% | |
Intangible Assets out of Total Assets |
0.10 | 0.11 | 0.11 | 0.11 | |
Share Based Compensation of Revenue |
12.08% | 17.02% | 14.24% | 14.36% | |
Graham Net Nets |
0.19 | 0.19 | 0.03 | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(38.37%) | (72.39%) | (23.37%) | (19.37%) | |
Free Cash Flow Yield |
(19.02%) | (30.00%) | (9.67%) | (6.39%) | |
Revenue per Share |
0.99 | 0.73 | 0.70 | 0.74 | |
Operating CF per Share |
(0.13) | 0.11 | (0.07) | (0.05) | |
Capex per Share |
(0.04) | (0.05) | (0.03) | (0.03) | |
Free Cash Flow per Share |
(0.16) | 0.06 | (0.11) | (0.08) | |
Cash per Share |
0.76 | 0.80 | 0.70 | 0.61 | |
Shareholders Equity per Share |
1.38 | 1.20 | 1.04 | 0.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.38 | 1.20 | 1.04 | 0.94 | |
Free Cash Flow |
(10.42) | 4.18 | (6.90) | (5.43) | |
Working Capital |
101.42 | 88.98 | 78.96 | 72.61 | |
Capital Expenditures |
(2.40) | (3.06) | (2.20) | (2.17) | |
Net Current Asset Value |
28.81 | 16.56 | 7.14 | 1.03 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.06 | 0.05 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
41.48 | 30.73 | 29.53 | 31.59 | |
Average Payables |
8.62 | 13.38 | 18.01 | 15.19 | |
Average Inventory |
37.64 | 37.15 | 40.97 | 41.86 | |
Average Assets |
203.84 | 194.97 | 193.75 | 187.95 | |
Average Common Equity |
100.11 | 91.27 | 82.68 | 75.42 |
Columns are period end dates · fundamentals updated 6 Nov 2026